Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00498927 · FLOW

Participant flow

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma · Source last updated 2016-02-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
    id
    FG000
    title
    Temozolomide
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
    id
    FG000
    title
    Temozolomide
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        47
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice